The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Prognostic factors in RET dependent cancers treateded with RET inhibitors in early phase clinical trials.
 
Max Gordon
No Relationships to Disclose
 
Jason Roszik
No Relationships to Disclose
 
Maria E. Cabanillas
Honoraria - Loxo/Lilly
Consulting or Advisory Role - Ignyta; Loxo
Research Funding - Eisai; Exelixis; Kura Oncology; Merck; Roche/Genentech
 
Mimi I-Nan Hu
Consulting or Advisory Role - Blueprint Medicines; Lilly; Loxo; Veracyte
 
Naifa Lamki Busaidy
Consulting or Advisory Role - Eisai; Loxo
 
Steven I. Sherman
Honoraria - Eisai
Consulting or Advisory Role - Exelixis; Lilly; Loxo
Research Funding - Exelixis (Inst)
 
Ramona Dadu
Consulting or Advisory Role - Bayer
 
Elizabeth Gardner Grubbs
No Relationships to Disclose
 
Yasir Y Elamin
Research Funding - AstraZeneca; Elevation Oncology; Lilly; Spectrum Pharmaceuticals; Takeda; Turning Point Therapeutics; Xcovery
Travel, Accommodations, Expenses - Lilly
 
Tina Cascone
Consulting or Advisory Role - MedImmune
 
Lauren Averett Byers
Consulting or Advisory Role - Abbvie; Alethia Biotherapeutics; AstraZeneca; Bristol-Myers Squibb; Debiopharm Group; Genentech; Genmab; Jazz Pharmaceuticals; Merck; Pfizer; PharmaMar; Sierra Oncology
Research Funding - AstraZeneca (Inst); Genmab (Inst); Sierra Oncology; Tolero Pharmaceuticals
 
George R. Blumenschein
Employment - Janssen (I); johnon & Johnson (I)
Stock and Other Ownership Interests - Virogin Biotech
Consulting or Advisory Role - Abbvie; Adicet Bio; Amgen; ARIAD; AstraZeneca; Bayer; Bristol-Myers Squibb; Celgene; Clovis Oncology; Daiichi Sankyo, INC; Genentech; Gilead Sciences; Johnson & Johnson (I); Maverick Therapeutics; MedImmune; Merck; Novartis; Novartis; Roche; Virogin Biotech; Xcovery
Research Funding - Adaptimmune; AstraZeneca; Bayer; BeiGene; Bristol-Myers Squibb; Celgene; Daiichi Sankyo INC; Exelixis; Genentech; GlaxoSmithKline; Immatics; Immunocore; Incyte; Kite, a Gilead company; Macrogenics; MedImmune; Merck; Novartis; Regeneron; Repertoire Immune Medicines; Roche; Tmunity Therapeutics, Inc.; Torque; Xcovery
 
Frank V. Fossella
No Relationships to Disclose
 
Aung Naing
Consulting or Advisory Role - CSL Behring (I); CytomX Therapeutics; Horizon Pharma (I); Kymab; Novartis; OncoSec; STCube Pharmaceuticals Inc.; Takeda (I)
Research Funding - Amplimmune; Arcus Biosciences; ARMO BioSciences; Atterocor; Baxalta (I); Bristol-Myers Squibb; Calithera Biosciences; Chao Physician-Scientist Awards; CytomX Therapeutics; EMD Serono; Healios; Immune Deficiency Foundation (I); ImmuneOncia; Incyte; Jeffrey Modell Foundation; Karyopharm Therapeutics; Kymab; Lilly; MedImmune; Merck; NCI; NeoImmuneTech; Neon Therapeutics; Novartis; Pfizer; PsiOxus Therapeutics; Regeneron; Surface Oncology; TopAlliance BioSciences Inc
Travel, Accommodations, Expenses - ARMO BioSciences
 
David S. Hong
Stock and Other Ownership Interests - MolecularMatch; OncoResponse; Presagia
Consulting or Advisory Role - Acuta; Adaptimmune; Alphasights; Amgen; Axiom Biotechnologies; Baxter; Bayer; Boxer Capital; COG; EcoR1 Capital; Genentech; Gerson Lehrman Group; GroupH; GroupH; Guidepoint Global; H.C. Wainwright & Co.; HCW Precision; Infinity Pharmaceuticals; Infinity Pharmaceuticals; Janssen; Medscape; Merrimack; Numab; Pfizer; Prime Oncology; Seagen; ST Cube; Takeda; Tavistock Life Sciences; Trieza Therapeutics; WebMD; WebMD
Research Funding - Abbvie (Inst); Adaptimmune (Inst); Aldai Norte (Inst); Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); BMS (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Erasca, Inc (Inst); Fate Therapeutics (Inst); Genentech (Inst); Genmab (Inst); Ignyta (Inst); Infinity Pharmaceuticals (Inst); Kite, a Gilead company (Inst); Kyowa (Inst); Lilly (Inst); Loxo (Inst); MedImmune (Inst); Merck (Inst); Mirati Therapeutics (Inst); miRNA Therapeutics (Inst); Molecular Templates (Inst); Mologen (Inst); National Cancer Institute (Inst); Navire (Inst); Novartis (Inst); Numab (Inst); Pfizer (Inst); Seagen (Inst); Takeda (Inst); Turning Point Therapeutics (Inst); Verastem (Inst); VM Pharma (Inst)
Travel, Accommodations, Expenses - AACR; ASCO; Bayer Schering Pharma; Genmab; Loxo; miRNA Therapeutics; Society for Immunotherapy of Cancer
 
John Heymach
Stock and Other Ownership Interests - Bio-Tree; Cardinal Spine
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; EMD Serono; Genentech/Roche; GlaxoSmithKline; Guardant Health; Hengrui Pharmaceutical; Lilly; Sanofi/Aventis; Spectrum Pharmaceuticals; Syntha Pharmaceutical; Takeda
Research Funding - AstraZeneca (Inst); Bayer; GlaxoSmithKline; Spectrum Pharmaceuticals
Patents, Royalties, Other Intellectual Property - Licensing agreement between Spectrum and MD Anderson (including myself) regarding intellectual property for treatment of EGFR and HER2 exon 20 mutations
 
Funda Meric-Bernstam
Employment - MD Anderson Cancer Center
Honoraria - Mayo Clinic; Rutgers Cancer Institute of New Jersey
Consulting or Advisory Role - Aduro Biotech; Alkermes; Debiopharm Group; eFFECTOR Therapeutics; Genentech; IBM; Immunomedics; Inflection Biosciences; Jackson Laboratory for Genomic Medicine; Kolon Life Sciences; Mersana; Origimed; PACT Pharma; Parexel International; Pfizer; Puma Biotechnology; Roche; Samsung Bioepis; Seagen; Silverback Therapeutics; Spectrum Pharmaceuticals; Tyra Biosciences; Xencor; Zentalis; Zymeworks
Speakers' Bureau - Chugai Pharma
Research Funding - Abbvie (Inst); Aileron Therapeutics (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (I); Calithera Biosciences (Inst); Curis (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Debiopharm Group (Inst); eFFECTOR Therapeutics (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Guardant Health (Inst); Jounce Therapeutics (Inst); Millennium (Inst); Novartis (Inst); Pfizer (Inst); PUMA Biotechnology (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - Beth Israel Deaconess Medical Center; Taiho Pharmaceutical
 
Vivek Subbiah
Consulting or Advisory Role - Helsinn Therapeutics; Loxo; MedImmune; QED Therapeutics; R-Pharm
Research Funding - Abbvie (Inst); Agensys (Inst); Alfasigma (Inst); Amgen (Inst); Amgen (Inst); Bayer (Inst); Berg Pharma (Inst); Blueprint Medicines (Inst); Boston Biomedical (Inst); D3 Oncology Solutions (Inst); Exelixis (Inst); Fujifilm (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Idera (Inst); Incyte (Inst); Inhibrx (Inst); LOXO (Inst); Multivir (Inst); NanoCarrier (Inst); Northwest Biotherapeutics (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); Takeda (Inst); Turning Point Therapeutics (Inst); Vegenics (Inst)
Travel, Accommodations, Expenses - Bayer; Helsinn Therapeutics; Novartis; PharmaMar
Other Relationship - Medscape